IN8BIO, INC. Restructuring Costs
IN8BIO, INC. (INAB) reported Restructuring Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2026-03-12
- IN8BIO, INC. restructuring costs for the quarter ending 2025-03-31 was $1.10M.
- IN8BIO, INC. restructuring costs for the quarter ending 2024-12-31 was $0.00.
- IN8BIO, INC. restructuring costs for the quarter ending 2024-09-30 was $1.10M.
- IN8BIO, INC. restructuring costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- IN8BIO, INC. restructuring costs for fiscal 2024 was $1.10M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | |||
| 2025-03-31 | $1.10M 10-Q · filed 2025-05-07 | $1.10M derived: sum of 2 quarters · filed 2026-03-12 | $2.20M derived: sum of 3 quarters · filed 2026-03-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.10M derived: sum of 2 quarters · filed 2026-03-12 | $1.10M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $1.10M 10-Q · filed 2024-11-12 | $1.10M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |